U.S. Markets open in 2 hrs 53 mins

Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?

ALLISON GATLIN
Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?

Novartis stock popped Friday as the Food and Drug Administration approved its gene therapy, Zolgensma, for spinal muscular atrophy treatment, throwing a challenge to Biogen and Ionis.